{"doi":"10.1101/2022.03.17.484817","title":"Potent and specific human monoclonal antibodies against SARS-CoV-2 Omicron variant by rapid mRNA immunization of humanized mice","abstract":"Abstract The Omicron variant (B.1.1.529) of SARS-CoV-2 rapidly becomes dominant globally. Its extensive mutations confer severe efficacy reduction to most of existing antibodies or vaccines. Here, we developed RAMIHM , a highly efficient strategy to generate fully human monoclonal antibodies (mAbs), directly applied it with Omicron-mRNA immunization, and isolated three potent and specific clones against Omicron. Rapid mRNA immunization elicited strong anti-Omicron antibody response in humanized mice, along with broader anti-coronavirus activity. Customized single cell BCR sequencing mapped the clonal repertoires. Top-ranked clones collectively from peripheral blood, plasma B and memory B cell populations showed high rate of Omicron-specificity (93.3%) from RAMIHM-scBCRseq. Clone-screening identified three highly potent neutralizing antibodies that have low nanomolar affinity for Omicron RBD, and low ng/mL level IC50 in neutralization, more potent than majority of currently approved or authorized clinical RBD-targeting mAbs. These lead mAbs are fully human and ready for downstream IND-enabling and/or translational studies.","journal":"bioRxiv (Cold Spring Harbor Laboratory)","year":2022,"id":301085,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":2,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.9532,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2022-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":246104,"name":"Lei Peng","orcid":"0000-0002-8217-2695","position":1,"is_corresponding":false},{"id":861702,"name":"Zhenhao Fang","orcid":"0000-0002-1246-3665","position":2,"is_corresponding":false},{"id":477698,"name":"Kazushi Suzuki","orcid":"0009-0008-9772-991X","position":3,"is_corresponding":false},{"id":259572,"name":"Paul Renauer","orcid":"0000-0002-8747-0552","position":4,"is_corresponding":false},{"id":861703,"name":"Qianqian Lin","orcid":"0000-0002-9196-7692","position":5,"is_corresponding":false},{"id":990807,"name":"Meizhu Bai","orcid":"0000-0001-8208-4073","position":6,"is_corresponding":false},{"id":862443,"name":"Luojia Yang","orcid":null,"position":7,"is_corresponding":false},{"id":688012,"name":"Tongqing Li","orcid":"0000-0002-5272-4380","position":8,"is_corresponding":false},{"id":259580,"name":"Paul Clark","orcid":"0009-0008-8399-5491","position":9,"is_corresponding":false},{"id":258664,"name":"Daryl E. Klein","orcid":"0000-0002-7188-0450","position":10,"is_corresponding":false},{"id":60778,"name":"Sidi Chen","orcid":"0000-0002-3819-5005","position":11,"is_corresponding":false},{"id":861705,"name":"Ping Ren","orcid":"0000-0002-6507-5180","position":0,"is_corresponding":true}],"reference_count":47,"raw_metadata":null,"created_at":"2026-07-19T00:31:57.812980Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}